Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake

 
• By Ayisha Sharma

The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.  

Silhouette of Stressed Woman combined with Dry Trees and Rain.
TRD Affects Around One-Third Of Patients Diagnosed With MDD • Source: Shutterstock

More from Clinical Trials

More from R&D